Skip to content
Pharma Observatory a Scientist.com platform

Organization (Academic)

Louisiana State University Health Sciences Center in New Orleans

ClinicalTrials.gov lists Louisiana State University Health Sciences Center in New Orleans as lead sponsor of 72 trials. It has 48 active development programs and 29 approved assets.

US Academic
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

17 0 1990 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 5 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 5 in 2026 and about 4 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 5 already registered with a 2026 start date: at the cutoff, 1 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts. 1 trial is registered to start in 2027 or later.

Logo LSU Health, 2011, via Wikimedia Commons, CC BY-SA 4.0. Shown to identify the organization; it may be a registered trademark.

This page covers Louisiana State University Health Sciences Center in New Orleans: 72 lead-sponsored trials and 0 legal-entity registrations.

Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.

Get the Louisiana State University Health Sciences Center in New Orleans report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (124)

Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).

Trials by start year as sponsor or collaborator (29)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 5
2025 4
2024 9
2023 11
2022 4
2021 17
2020 8
2019 6
2018 7
2017 7

Prediction, not a registry value: median 36 months or more (the model's horizon) from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; 5 of 7 predicted trials reach the 36-month horizon; registered median of 22 months across 36 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (48)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
MMR (Measles, Mumps, and Rubella) Vaccine COVID-19 Phase 3 1
MMR (Measles, Mumps, and Rubella) Vaccine Sepsis Phase 3 1
MMR (Measles, Mumps, and Rubella) Vaccine Inflammation Phase 3 1
Tranexamic Acid (TXA) treatment Anemia Phase 2/3 1
Phentermine-Topiramate combination Insulin Resistance Not reported 1

Approved assets (29)

Shown in this order: max phase first.

Approved assets
Drug Trials
Dehydrated human amnion/chorion membrane 2
2% Lidocaine with 1:100,000 epinephrine 2
human papillomavirus vaccine, recombinant 1
Proparacaine Hydrochloride ophthalmic solution, USP 0.5% 1
Lubricant Gel 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
18% hit target (n=17) 23% on time (n=13)

Biomarker capability evidence (54)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ALB Trial sponsor Named in trial inclusion criteria
CD4 Trial collaborator Named in trial inclusion criteria
CD4 Trial sponsor Named in trial inclusion criteria
CD4 Trial sponsor Named in trial inclusion criteria
F2 Trial sponsor Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.

Counted at group level under Louisiana State University System: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.